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Renal impairment is a major concern in patients taking high‑dose methotrexate (MTX) for malignancy, 
but it has not been fully explored in rheumatoid arthritis (RA) patients taking low‑dose MTX. This 
study aimed to elucidate the dose‑dependent effects of MTX on the renal function of patients with 
RA. We retrospectively reviewed 502 consecutive RA patients who were prescribed MTX for ≥ 1 year 
at Okayama University Hospital between 2006 and 2018. The primary outcome was the change in 
estimated glomerular filtration rate (eGFR) over 1 year. The association between MTX dosage (< 8, 
8–12, and ≥ 12 mg/week) and the change in eGFR was evaluated using multiple linear regression 
analysis with adjustment for possible confounding factors including age, sex, disease duration, 
body weight, comorbidity, baseline eGFR, concomitant treatment, and disease activity. Mean 
patient age was 63 years; 394 (78%) were female. Median disease duration was 77 months, while 
mean MTX dosage was 8.6 mg/week. The last 1‑year change of eGFR (mean ± SD) in patients treated 
with MTX < 8 (n = 186), 8–12 (n = 219), ≥ 12 mg/week (n = 97) decreased by 0.2 ± 7.3, 0.6 ± 8.6, and 
4.5 ± 7.9 mL/min/1.73  m2/year, respectively (p < 0.0001). After adjustment for the confounding factors, 
MTX ≥ 12 mg/week was still correlated with a decrease in 1‑year eGFR (beta‑coefficient: − 2.5; 95% 
confidence interval, − 4.3 to − 0.6; p = 0.0089) in contrast to MTX 8–12 mg/week. Careful monitoring 
of renal function is required in patients with MTX ≥ 12 mg/week over the course of RA treatment 
regardless of disease duration.
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The last decade has been seen the drastic paradigm shifts in the treatment of rheumatoid arthritis (RA). Few 
efficient conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) have been developed, 
of which methotrexate (MTX) became available first, followed by biological agents. Among those treatment 
options, MTX is the promised anchor drug that should be firstly considered for use in patients diagnosed with 
 RA1. Although it is recommended that MTX be rapidly escalated to the maximum tolerated dosage (25–30 mg/
week), the optimal dosage might be lower for Asian  patients1–3.
Chronic kidney disease (CKD) occurs more frequently in patients with RA than in the general  population4,5. 
Previous reports showed that with treatment options, such as bucillamine and nonsteroidal anti-inflammatory 
drugs (NSAIDs)4,6, secondary  amyloidosis6 and chronic  inflammation7 were risk factors for renal impairment in 
RA patients, while the use of biological DMARDs was associated with a lower risk of renal  impairment8. Although 
renal impairment is a major concern in patients taking high-dose MTX for the treatment of malignancy, it has not 
been fully examined in RA patients treated with low-dose MTX. A case series of patients with RA suggested that 
renal impairment was caused by  MTX9, whereas another showed that MTX and its dosage were not associated 
with the detection of abnormal estimated glomerular filtration rate (eGFR) (< 90 mL/min/1.73  m2)10.
This study aimed to elucidate the dose-dependent effects of MTX on renal function by evaluating the associa-
tion between MTX dosage and the 1-year change of eGFR in RA patients.
Patients and methods
Study design and patient selection. We retrospectively reviewed 502 consecutive patients with RA who 
were prescribed oral MTX for ≥ 1 year at Okayama University Hospital between April 2006 and March 2018. All 
patients fulfilled American College of Rheumatology/European League Against Rheumatism 2010 Classification 
Criteria for  RA11. Exclusion criteria were: (1) < 20 years of age, (2) nephrotic syndrome, (3) unilateral kidney, and 
(4) rheumatic disorders other than secondary Sjögren’s syndrome.
Data collection. Clinical data during the most-recent 1-year exposure to MTX between April 2006 and 
March 2018 was collected through electronic medical records. The following information was collected at 
start of the observational period as baseline data: age, sex, disease duration, body weight, body mass index 
(BMI), prednisone use and dose, NSAID use, use of csDMARDs, use of biological DMARDs (bDMARDs), 
use of targeted synthetic DMARDs (tsDMARDs), hypertension (receiving treatment and/or blood pressure 
above 140/90 mmHg), diabetes (receiving treatment and/or Hemoglobin A1c [HbA1c] above 6.5%), second-
ary Sjögren’s syndrome, white blood cell (WBC) count, hemoglobin (Hb), platelet count, serum creatinine 
(s-Cr) levels, proteinuria (> 0.5 g/gCr and/or ≥ 2 + on dipstick urinalysis), erythrocyte sedimentation rate (ESR), 
C-reactive protein (CRP) level, 28-joint Disease Activity Score (DAS28)-CRP, Simplified Disease Activity Index 
(SDAI), Clinical Disease Activity Index (CDAI), and Health Assessment Questionnaire (HAQ) results. MTX 
dosage was calculated as the mean dosage (mg/week) during the 1-year observational period.
Outcome. The primary outcome measure was the change in eGFR during the previous 1  year for each 
patient. The eGFR was calculated by the equation defined by the Japanese Society of Nephrology: eGFR (mL/
min/1.73  m2) = 194 × (serum creatinine [mg/dl])−1.094 × (age)−0.287 × 0.739 (if female)12.
Statistical analysis. Clinical characteristics are presented as mean ± standard deviation (SD) or median 
(interquartile range; IQR) for continuous variables and patient number (%) for categorical variables. One-way 
analysis of variance (one-way ANOVA) was used for continuous variables, and Fisher’s exact tests were used for 
categorical variables to compare outcomes and patient characteristics among patients with different MTX dos-
ages: < 8, 8–12, and ≥ 12 mg/week. The cutoff for the dosage of MTX was determined by the reference of Japan 
College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis; 8 mg, at 
which is recommended as the initial dose, 12 mg, to which is recommended in patients showing inadequate 
response to the initial dose of MTX, and further dose-escalation of MTX to 16 mg/week (approved maximum 
dose in Japan) was optional according to the risk–benefit in each  patient13.
To adjust for confounding factors using multiple linear regression analysis, possible confounders were selected 
according to the univariate analysis results and the findings of previous reports on risk factors on renal impair-
ment. As for MTX dose groups with significantly higher risk of renal impairment in the regression analysis, 
the change of eGFR was followed for the extended 5-year period in patients whose laboratory data could be 
obtained, in order to observe the accumulative effect. Missing data for disease duration, body weight, BMI, 
ESR, and DAS28-ESR/CRP, and HAQ findings were imputed by multivariate normal imputation using the least 
squares method.
Statistical testing was two-sided, and values of p < 0.05 were considered statistically significant. For the com-
parison of three categories, statistical significance was determined by p < 0.05/3 using Bonferroni correction to 
avoid multiplicity. All statistical analyses in this study were performed using JMP for Windows version 12.2.0 
(SAS Institute Inc., Cary, NC, USA).
Ethics approval and consent to participate. This study was conducted according to the guidelines of 
the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Sub-
jects in Japan. The study has received approval from the ethics committees of the Okayama University Graduate 
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School of Medicine, Dentistry, and Pharmaceutical Sciences (authorization number: Ken 1809-022), and the 
need to obtain written informed consent was waived due to retrospective nature of the study, where participants 
consent was implied by an opt-out approach.
Results
Patient characteristics and MTX dosage. The patient selection flowchart is shown in Fig. 1. The miss-
ing data (n = 182) derived from the following two reasons; (1) insufficient prescription data when patients did 
not receive prescriptions at our institution, but at other local clinics, (2) incomplete records during the tran-
sitional period of our electrical medical record system. The mean ± SD age of the enrolled 502 patients was 
63 ± 13 years; 394 (78%) were female. The median (IQR) disease duration was 77 (31–159) months. The mean 
MTX dosage was 8.6 ± 3.0  mg/week, and bDMARDs or tsDMARDs were concomitantly used in 140 (27%) 
patients. The eGFR (mean ± SD) decreased by 1.2 ± 8.1 mL/min/1.73  m2 from 76.1 ± 17.3 mL/min/1.73  m2 dur-
ing the 1-year observational period.
Comparison among different MTX dosage groups. The enrolled patients were divided into three 
groups according to MTX dosage: < 8 mg/week, n = 186 (37%); 8–12 mg/week, n = 219 (43%); and ≥ 12 mg/week, 
n = 97 (19%).
A comparison of patient characteristics among these MTX dosage groups is shown in Table 1. Patients in 
the MTX ≥ 12 mg/week group were younger, had a higher baseline eGFR, and had a higher mean body weight 
than those in the MTX < 8 mg/week or 8–12 mg/week groups. The concomitant use of NSAIDs was significantly 
less frequent in patients in the MTX < 8 mg/week group than in those in the other two groups. The concomitant 
use of bDMARDs or tsDMARDs was more frequent in a dose-dependent manner with MTX but the difference 
between the groups was not significantly different. All disease activity scores were significantly higher with MTX 
use in a dose-dependent manner.
Change in eGFR among different MTX dosage groups. The eGFR in patients treated with 
MTX < 8 mg/week, 8–12 mg/week, and ≥ 12 mg/week decreased by 0.2 ± 7.3, 0.6 ± 8.6, and 4.5 ± 7.9 mL/min/1.73 
 m2/year, respectively (p < 0.0001; Fig. 2). In the multivariate analysis, the following variables were selected as 
confounding factors based on the results of univariate analysis and previous reports: age, sex, disease duration, 
body weight, baseline eGFR, hypertension, diabetes, concomitant use of NSAIDs and bDMARDs/tsDMARDs, 
and DAS28-CRP4,6–8. After the adjustment for confounding factors using multiple linear regression analysis, the 
use of MTX < 8 mg/week did not significantly change the eGFR (beta-coefficient: − 0.86; 95% confidence inter-
val [CI] − 0.65 to 2.36; p = 0.26) but that of MTX ≥ 12 mg/week was still correlated with a statistically significant 
decrease in eGFR (beta-coefficient: − 2.46; 95% CI − 4.30 to − 0.62; p = 0.0089) in contrast to MTX 8–12 mg/week 
use (Table 2). In addition, we observed the change of eGFR in the MTX ≥ 12 mg/week group patients for the 
5-year extended period to ascertain the effect could accumulate. We could collect follow-up data of 62 patients 
Figure 1.  Patient selection flowchart.
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Table 1.  Comparison of patients according to dosage: MTX < 8, 8–12, or ≥ 12 mg/week. BMI Body Mass 
Index, b/tsDMARDs biological/targeted synthetic disease-modifying antirheumatic drug, CDAI clinical disease 
activity index, CKD chronic kidney disease, CRP C-reactive protein, DAS28 28-joint Disease Activity Score, 
eGFR estimated glomerular filtration rate, ESR erythrocyte sedimentation rate, HAQ Health Assessment 
Questionnaire, IQR interquartile range, NSAIDs nonsteroidal anti-inflammatory drugs, RASi renin-angiotensin 
system inhibitor, SD standard deviation, SDAI Simplified Disease Activity Index, WBC white blood cells. 
*p < 0.05 for comparison between patients with different MTX dosage groups.
All
N = 502
 < 8 mg
n = 186
8–12 mg
n = 219
 ≥ 12 mg
n = 97 p value
Age, mean ± SD, years 63 ± 13 65 ± 13 61 ± 14 58 ± 13 0.0005*
Female, n (%) 394 (78%) 155 (83%) 172 (79%) 67 (69%) 0.02*
Disease duration, median (IQR), months 77 (31–159) 79 (24–196) 77 (33–134) 77(34–150) 0.03*
CKD, n (%) 86 (17%) 56 (30%) 27 (12%) 3 (3%)  < 0.0001*
Baseline eGFR, mean ± SD, mL/min/1.73  m2 76.1 ± 17.3 70.4 ± 17.9 77.3 ± 15.6 84.3 ± 16.1  < 0.0001*
ΔeGFR, mean ± SD, mL/min/1.73  m2  − 1.17 ± 8.1  − 0.19 ± 7.3  − 0.56 ± 8.6  − 4.48 ± 7.9  < 0.0001*
Body weight, mean ± SD, kg 54.4 ± 11.7 52.1 ± 9.7 55.1 ± 12.4 57.3 ± 12.7 0.0009*
BMI, mean ± SD, kg/m2 22.0 ± 3.7 21.6 ± 3.1 22.4 ± 3.9 22.2 ± 4.0 0.10
Sjögren’s syndrome, n (%) 24 (4.8%) 15 (8%) 7 (3%) 2 (2%) 0.03*
ILD, n (%) 21 (4%) 5 (3%) 11 (5%) 5 (5%) 0.44
Diabetes mellitus, n (%) 54 (11%) 22 (12%) 24 (11%) 8 (8%) 0.65
Hypertension, n (%) 180 (36%) 70 (39%) 78 (36%) 32 (33%) 0.74
Methotrexate dosage, mean ± SD, mg/kg 8.6 ± 3.0 5.6 ± 1.4 9.2 ± 1.1 13.1 ± 1.3  < 0.0001*
Folic acid, n (%) 337 (67%) 111 (60%) 154 (70%) 72 (74%) 0.02*
NSAIDs, n (%) 193 (38%) 59 (32%) 80 (37%) 54 (56%) 0.0003*
Prednisolone, n (%) 210 (42%) 66 (35%) 99 (45%) 45 (46%) 0.08
Prednisolone dose, mg ± SD 3.8 ± 1.2 3.5 ± 1.8 4.1 ± 2.8 3.9 ± 2.2 0.28
Salazosulfapyridine, n (%) 62 (12%) 28 (15%) 22 (10%) 12 (12%) 0.31
Iguratimod, n (%) 25 (5%) 5 (3%) 14 (6%) 6 (6%) 0.19
Bucillamine, n (%) 26 (5%) 8 (4%) 10 (5%) 8 (8%) 0.31
Tacrolimus, n (%) 73 (15%) 23 (12%) 30 (14%) 20 (21%) 0.16
Hydroxychlorquine, n(%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) –
b/tsDMARDs, n (%) 140 (27%) 47 25% 59 27% 34 (35%) 0.20
Infliximab, n (%) 34 (7%) 10 (5%) 15 (7%) 9 (9%) 0.46
Adalimumab, n (%) 17 (3%) 7 (4%) 6 (3%) 4 (4%) 0.77
Golimumab, n (%) 9 (2%) 0 (0%) 7 (3%) 2 (2%) 0.05
Certolizumab pegol, n (%) 8 (2%) 4 (2%) 1 (0.5%) 3 (3%) 0.17
Etanercept, n (%) 49 (10%) 20 (11%) 20 (9%) 9 (9%) 0.85
Tocilizumab, n (%) 9 (2%) 3 (2%) 4 (2%) 2 (2%) 0.96
Abatacept, n (%) 12 (2%) 3 (2%) 5 (2%) 4 (4%) 0.42
Tofacitinib, n (%) 4 (0.7%) 0 (0%) 1 (0.5%) 3 (3%) 0.016*
RASi, n (%) 80 (16%) 35, (19%) 33 (15%) 12 (12%) 0.33
DAS28-ESR, mean ± SD 3.1 ± 1.1 3.0 ± 1.0 3.1 ± 1.0 3.4 ± 1.2 0.04*
DAS28-CRP, mean ± SD 2.4 ± 0.9 2.2 ± 0.8 2.4 ± 0.9 2.7 ± 1.1 0.0019*
SDAI, median (IQR) 5.8 (2.8–9.3) 5.3 (2.2–8.6) 5.7 (3.4–9.3) 6.8 (3.2–11.6) 0.0032*
CDAI, median (IQR) 5.4 (2.5–8.6) 5.0 (2.0–8.1) 5.4 (3.1–8.6) 6.4 (2.7–10.7) 0.0040*
HAQ, median (IQR) 0.4 (0–0.7) 0.4 (0.1–0.8) 0.4 (0–0.6) 0.4 (0.1–0.8) 0.18
Proteinuria, n (%) 7 (1%) 3 (2%) 3 (1%) 1 (1%) 0.92
WBC, mean ± SD, /µL 6.25 ± 2.23 5.99 ± 2.37 6.35 ± 2.21 6.49 ± 1.97 0.13
Hemoglobin, mean ± SD, g/dL 12.7 ± 1.4 12.7 ± 1.4 12.6 ± 1.4 12.7 ± 1.4 0.92
Platelet count, mean ± SD,  103/µL 249 ± 73 237 ± 70 255 ± 78 255 ± 64 0.03*
Blood urea nitrogen, mean ± SD, mg/dL 15.3 ± 4.4 16.0 ± 5.1 15.1 ± 4.0 14.6 ± 3.5 0.03*
Serum creatinine, mean ± SD, mg/dL 0.68 ± 0.16 0.72 ± 0.18 0.66 ± 0.14 0.64 ± 0.12  < 0.0001*
ESR, mean ± SD, mm/h 30 ± 24 31 ± 26 30 ± 24 31 ± 23 0.84
CRP, mean ± SD, mg/dL 0.66 ± 1.26 0.55 ± 1.16 0.68 ± 1.30 0.83 ± 135 0.20
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out of the 97 patients who received MTX ≥ 12 mg/week. The eGFR in patients treated with MTX ≥ 12 mg/week 
decreased 13.8 ± 10.4 mL/min/1.73  m2 over 5-year period.
Dicussion
In the present study, eGFR decreased by 1.2 mL/min/1.73  m2 over 1 year, but the larger decrease was seen in a 
higher dose MTX administration.
Renal impairment may persist over the course of treatment regardless of a disease duration in patients with 
RA receiving higher dose MTX. Significant nephrotoxicity occurs in 2–12% of patients treated with high-dose 
intravenous MTX for  malignancy14. Nephrotoxicity is reportedly caused by crystal nephropathy due to the pres-
ence of MTX and its metabolites in the renal tubules; therefore, monitoring of plasma MTX concentrations, 
hydration, and urine alkalinization are recommended during  treatment14. In cases of low-dose MTX treatment 
for RA, renal impairment caused by MTX is not mentioned in clinical practice  guidelines1,13,15. However, there are 
some previous reports on renal impairment in RA patients upon the initiation of  MTX9,10,16. Our study evaluated 
the change in eGFR during the previous 1 year in patients with a mean disease duration of 10 years. Therefore, 
renal impairment due to low-dose MTX can persist and progress over the long term after the initiation of MTX. 
MTX dosage was not reportedly associated with the detection of an abnormal eGFR (< 90 mL/min/1.73  m2)10. 
However, this previous report showed that eGFR in patients taking MTX > 15 mg/week (n = 29) and those tak-
ing MTX < 15 mg/week (n = 72) decreased by 6.8 and 8.8 mL/min/1.73  m2, respectively, during the mean 4-year 
observational period. The adequate sample size of our study enabled confirmation of the statistically significant 
differences in dose dependency even after the adjustment for confounding factors.
CKD was detected in 17% of the enrolled patients in this study. Previous reports showed that CKD occurred 
slightly more frequently in patients with RA than in the general  population5,17–20. The prevalence of CKD in the 
present study was consistent with that in previous  reports5,19,20. Because the administration of MTX should be 
avoided in RA patients with renal failure, a lower prevalence of CKD was expected in the present study than in 
these previous reports. Although risk factors for renal impairment such as some drugs and chronic inflamma-
tion have been  reported4,6,7,20, MTX may also be an important risk factor for CKD in patients with RA. Although 
a decrease by 4.5 mL/min/1.73  m2/year seems small, the accumulated effects might be considerable and may 
lead to significant progression of CKD, which are demonstrated in our study by the 13.8 mL/min/1.73  m2 mean 
decrease of eGFR over 5 year period in patients with higher dose of MTX.
There are some limitations to this study. First, the MTX dosages were smaller than those in other clinical 
 studies21,22. In Japan, the maximum recommended dose of MTX is 16 mg/week, which more than half of Japanese 
patients with RA cannot  tolerate13. Therefore, our results suggest that patients treated with MTX should be moni-
tored for renal impairment even in common clinical situations. Second, the mean MTX dosage was calculated 
during the observational period; thus, fluctuations in dosage were not considered. Although some patients may 
reduce the MTX dosage due to the progression of renal impairment, our result was not overestimated because 
these patients would be categorized into lower dosage groups.
Figure 2.  Change in eGFR over 1-year period among different MTX dosage groups.
Table 2.  Association of MTX dosage with change in eGFR assessed using multiple linear regression analysis. 
Age, sex, disease duration, body weight, baseline eGFR, hypertension, diabetes, concomitant use of NSAIDs, 
concomitant use of b/tsDMARDs, and DAS28-CRP were used in the multiple linear regression models to 
adjust for confounding factors related to MTX dosage and renal impairment. b/tsDMARDs biological/targeted 
synthetic disease-modifying antirheumatic drug, CRP C-reactive protein, DAS28 28-joint Disease Activity 
Score, eGFR estimated glomerular filtration rate, NSAIDs nonsteroidal anti-inflammatory drugs.
βcoefficient SD p value 95% confidence interval forβ
MTX < 8 mg/week (vs. 8 ≤ MTX < 12 mg/week) 0.86 0.77 0.26  − 0.65 to 2.36
MTX ≥ 12 mg/week (vs. 8 ≤ MTX < 12 mg/week)  − 2.46 0.94 0.0089  − 4.30 to − 0.62
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In conclusion, careful monitoring of renal function should be required in treatment with MTX ≥ 12 mg/week 
among RA patients.
Data availability
The datasets used and analyzed during the current study are available from the corresponding author upon 
reasonable request.
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